Equity method investment - Variable Interest Entity
Variable Interest Entity Disclosure [Text Block]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative
Document Transition Report
Document Transition Report
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Expected volatility
Money Market Funds [Member]
Money market funds [Member]
Description of operations policy.
Description Of Operations Policy Policy [Text Block]
Description of Operations
Clinical development milestone.
Clinical Development Milestones [Member]
Clinical and Development Milestone [Member]
Net of commissions to sales agents
Payments of Stock Issuance Costs
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent
Restructuring plan, expected reduction to workforce, percentage
Basis of presentation and principles of consolidation policy.
Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block]
Basis of Presentation and Principles of Consolidation
Geographical [Axis]
Geographical
Accounting Standards Update 2014-09 [Member]
ASC 606 [Member]
API shipment.
A P I Shipment [Member]
API Shipment [Member]
HiFiBiO agreement.
Hi Fi Bi O Agreement [Member]
HiFiBiO Agreement [Member]
Noncontrolling Interest [Member]
Noncontrolling Interests [Member]
Revenue resulting from changes to estimated variable consideration.
Revenue Resulting from Changes to Estimated Variable Consideration
Revenue resulting from changes to estimated variable consideration
Cost of Revenue
Cost of goods sold
Cost of Revenue, Total
Debt Securities, Available-for-Sale
Fair Value
Investments
Estimated Fair Value
Astellas agreements.
Astellas Collaboration Agreement [Member]
Astellas Agreement [Member]
Other long-term liabilities ($668 and $0 to a related party)
Other long-term liabilities
Other Liabilities, Noncurrent
Total other long-term liabilities
Nonredeemable Noncontrolling Interest
Nonredeemable non-controlling interests
Increase (Decrease) in Prepaid Expense and Other Assets
Prepaid expenses and other current assets
Increase (Decrease) in Prepaid Expense and Other Assets, Total
Redeemable Noncontrolling Interest, Equity, Carrying Amount, Total
Redeemable Noncontrolling Interest, Equity, Carrying Amount
Redeemable non-controlling interests
Schedule of lease assets and related lease liabilities.
Schedule Of Lease Assets And Related Lease Liabilities Table [Text Block]
Schedule of Lease Assets and Related Lease Liabilities
Fair Value, Inputs, Level 1 [Member]
Level 1 [Member]
Valuation Technique, Discounted Cash Flow [Member]
Discounted Cash Flow [Member]
Fair Value Disclosures [Text Block]
Fair Value Measurements
Revenue from Contract with Customer, Excluding Assessed Tax
Total revenue
Revenue from Contract with Customer, Excluding Assessed Tax, Total
Drug product revenue recognized
Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized
Changes in revenue from changes to estimated variable consideration
Drug product revenue.
Drug Product Revenue [Member]
Drug Product Revenue, Net [Member]
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations and Product Revenue Net
Disaggregation of Revenue [Table Text Block]
Recently issued accounting guidance not yet adopted.
Recently Issued Accounting Guidance Not Yet Adopted Policy [Text Block]
Recently Issued Accounting Guidance Not Yet Adopted
Schedule of Business Acquisitions, by Acquisition [Table]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3
Transfers of assets into level 3
Deferred revenue ($5,482 and $9,259 to related parties)
Deferred Revenue
Profit share liability
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
Schedule of Allocation of Purchase Consideration Based on Estimated Fair Values of Acquired Assets
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months
Available for sale securities in continual unrealized loss position, less than 12 months, estimated fair value
Subsequent Event
Subsequent Events [Text Block]
Equity Method Investment, Nonconsolidated Investee [Axis]
Equity Method Investment, Nonconsolidated Investee
Biosynthetic Cornea [Member]
biosynthetic Cornea [Member]
Biosynthetic Cornea.
Debt instrument accrued interest.
Debt Instrument Accrued Interest
Accrued interest
Operating Lease, Liability, Noncurrent
Operating lease liabilities, non-current
Operating lease liabilities
Unrestricted cash and cash equivalent balance maintain in accounts.
Unrestricted Cash And Cash Equivalent Balance Maintain In Accounts
Unrestricted cash and cash equivalent balance required to maintain in accounts
Commercial sales and other events milestone.
Commercial Sales And Other Events Milestone
Commercial sales and other events milestone
Europe [Member]
Europe [Member]
Accrued API and bulk drug product price true-up current.
Accrued API and bulk drug product price true-up current
API and bulk drug product price true-up
Collaborative arrangements license agreement and revenues.
Collaborative Arrangements License Agreement And Revenues Policy [Text Block]
Collaboration Agreements, License Agreement and Revenues
Number of identified performance obligation at inception of agreement.
Number Of Identified Performance Obligation At Inception Of Agreement
Number of identified performance obligation at inception of agreement
Related Party Transactions [Abstract]
Balance Sheet Location [Axis]
Balance Sheet Location
Payment Cap Date on or after January 1, 2029 [Member]
Payment cap date on or after January one two thousand twenty nine [Member]
Payment cap date on or after January one two thousand twenty nine.
Assets, Current
Total current assets
Accumulated Amortization, Debt Issuance Costs
Issuance costs, amortised
Liabilities and Equity
Total liabilities, redeemable non-controlling interests and deficit
Proceeds from sales of available for sale securities
Proceeds From Sales Of Available For Sale Securities
Proceeds from sales of available-for-sale securities
Entity Address, State or Province
Entity Address, State or Province
Percentage of product manufacturing costs until manufacturing technology fully transferred.
Percentage Of Product Manufacturing Costs Until Manufacturing Technology Fully Transferred
Percentage of product manufacturing costs until manufacturing technology fully transferred
Transaction [Domain]
Transaction
Fair value assets level2 to level1 transfer amount.
Fair Value Assets Level2 To Level1 Transfer Amount
Transfers of assets from level 2 to 1
Issuance of common stock under ATM Program
Stock Issued During Period, Value, New Issues
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted average estimated fair value
Comprehensive loss
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Trading Symbol
Trading Symbol
Common Stock, Shares, Issued
Common stock, shares issued
Common Stock, Shares, Issued, Total
Debt Securities, Available-for-Sale [Line Items]
Schedule of Available-for-sale Securities [Line Items]
Operating Costs and Expenses [Abstract]
Operating costs and expenses:
Revenue Interest Financing Agreement [Member]
Revenue Interest Financing Agreement.
Accounts receivable from related parties
Accounts Receivable Net Current Related Parties
Accounts receivable net current related parties.
Collaborative arrangement aggregate consideration.
Collaborative Arrangement Aggregate Consideration
Aggregate considerations received
Prepaid Expense and Other Assets, Current
Total prepaid expenses and other current assets
Prepaid expenses and other current assets
Contract with customer liability deduction.
Contract With Customer Liability Deduction
Deduction
Transaction costs related to sale of future revenues
Payments For Transaction Costs Related To Sale Of Future Revenues
Payments for transaction costs related to sale of future revenues.
Repayments of Secured Debt
Cash paid for transaction costs for senior secured term loan facilities
Repayments of finance lease liabilities.
Repayments Of Finance Lease Liabilities
Financing cash flows from finance leases
Repayments of finance lease liabilities
Schedule of Long-Term Debt Instruments [Table]
Shares, Outstanding
Balance, Shares
Balance, Shares
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Business Combination Disclosure [Text Block]
Exclusive License and Option to Acquire Fortis Therapeutics
Other comprehensive gain (loss), net of taxes
Other Comprehensive Income (Loss), Net of Tax
Repayment description.
Repayment Description
Repayment description
Contract liabilities,
Contract Liabilities [Member]
Contract Liabilities [Member]
Increase (decrease) in operating lease liabilities, current.
Increase Decrease In Operating Lease Liabilities Current
Operating lease liabilities, current
Equity Method Investments [Table Text Block]
Summary of Equity Method Investment
Entity Address, City or Town
Entity Address, City or Town
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Due to related parties deferred revenue noncurrent.
Due To Related Parties Deferred Revenue Noncurrent
Deferred revenue non-current to related party
Debt Disclosure [Text Block]
Senior Secured Term Loan Facilities
Development and other revenue.
Development and Other Revenue [Member]
Development Revenue [Member]
Other Revenue - Contract Manufacturing [Member]
Represents the long-term portion of the outstanding principal and accrued interest of advances in the form note agreements received by the entity to fund various product development efforts.
Accrued Product Development Costs
Product development obligations
Subsequent Event [Member]
Subsequent Event Type [Axis]
Accrued and other current liabilities to related party
Other Liabilities Current Due to Related Parties
Other liabilities current due to related parties.
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Inventory, Raw Materials, Gross
Raw materials
Inventory, Raw Materials, Gross, Total
Liabilities, Current [Abstract]
Current liabilities:
Cash Acquired from Acquisition
Cash acquired from consolidation of Fortis
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer
Available for sale securities in continual unrealized loss position, 12 months or more, estimated fair value
Assets, Current [Abstract]
Current assets:
Counterparty Name [Axis]
Preferred Stock, Par or Stated Value Per Share
Preferred stock, par value
Statement of Stockholders' Equity [Abstract]
Debt Financing Agreement [Member]
Debt financing agreement.
Operating Lease, Liability, Current
Operating lease liabilities, current
Operating lease liabilities
Debt Instrument, Maturity Date
Maturity date
Long-Term Debt
Term loan
Senior secured term loan facilities, ending balance
Property, Plant and Equipment, Net
Property and equipment, net
Property and equipment, net
Property, Plant and Equipment, Net, Beginning Balance
Property, Plant and Equipment, Net, Ending Balance
Series A Preferred Stock [Member]
Series A Preferred Shares [Member]
Class of Stock [Domain]
Restructuring charge
Restructuring Charges, Total
Restructuring Charges
Restructuring plan, non-recurring charges
Liability related to sale of future revenues, non-current
Liability Related To Sale Of Revenues NonCurrent
Liability related to sale of revenues noncurrent.
Statement of Comprehensive Income [Abstract]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Entity Central Index Key
Entity Central Index Key
US Treasury and Government [Member]
U.S. government bonds [Member]
Loss on disposal of property and equipment
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property
Loss (gain) on disposal of property and equipment
Assets, Fair Value Disclosure, Total
Assets, Fair Value Disclosure
Total fair value of financial assets
Increase (Decrease) in Other Operating Assets
Other assets
Increase (Decrease) in Other Operating Assets, Total
Preferred Stock, Shares Outstanding
Preferred stock, shares outstanding
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred Stock, Shares Outstanding, Ending Balance
Current portion classified to accrued and other current liabilities.
Current Portion Classified to Accrued and Other Current Liabilities
Less: Current Portion classified to accrued and other current liabilities
Liabilities, Current
Total current liabilities
Entity Tax Identification Number
Entity Tax Identification Number
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]
The amount of additional consideration based on net sales of product as defined under a collaboration agreement.
Additional Consideration Based On Net Sales
Additional consideration based on net sales description
Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions.
Schedule Of Share Based Payment Award Stock Options And Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]
Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Purchases under 2014 Employee Share Purchase Plan
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Increase (Decrease) in Operating Capital [Abstract]
Changes in operating assets and liabilities:
Property taxes and other current.
Property Taxes And Other Current
Property taxes and other taxes
Financial Instruments [Domain]
Collaborative arrangement additional upfront payments.
Collaborative Arrangement Additional Upfront Payments
Additional upfront payments
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue and the amount of consideration recognized during the period for milestones. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, non-specified, services during the reporting period.
License Fees And Milestones Revenue
License and milestone revenue from a related party
Award Date [Domain]
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted average shares used to compute net income (loss) per share:
Weighted average number of common shares used to calculate net loss per share:
Investment, Name [Axis]
Initial Term Loan [Member]
Initial Term Loan [Member]
Initial Term Loan [Member]
Cash and Cash Equivalents [Abstract]
Miscellaneous receivables.
Miscellaneous Receivables
Miscellaneous receivables
Equity Method Investment, Nonconsolidated Investee [Domain]
Equity Method Investment, Nonconsolidated Investee
Geographical [Domain]
Geographical
Assets
Total assets
UNITED STATES
U.S. [Member]
Operating Lease, Right-of-Use Asset
Operating lease right-of-use assets
Operating lease right-of-use assets, net
Non-cash interest expense related to drug product revenue
Non-cash interest expense related to drug product revenue
Non-cash interest expense related to drug product revenue
Reduction of accrued and other current liabilities
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Accrued and other liabilities
Gross proceeds received from sale of revenue
Gross proceeds received from sale of revenue
Gross proceeds received from sale of revenue.
Entity Registrant Name
Entity Registrant Name
Asset-Backed Securities [Member]
Asset-backed securities [Member]
Debt Issuance Costs, Net, Total
Debt Issuance Costs, Net
Issuance cost
Related Party, Type [Domain]
Related Party
Retained Earnings (Accumulated Deficit)
Accumulated deficit
Retained Earnings (Accumulated Deficit), Total
Retained Earnings (Accumulated Deficit), Beginning Balance
Retained Earnings (Accumulated Deficit), Ending Balance
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Available for sale securities in continual unrealized loss position, less than 12 months, gross unrealized holding losses
Prepayment amount of 2024 to 2030
Prepayment amount
Prepayment amount.
Commercial milestone.
Commercial Milestone
Commercial milestone
Retained Earnings [Member]
Accumulated Deficit [Member]
Class of Stock [Axis]
Total deficit
Equity, Including Portion Attributable to Noncontrolling Interest
Balance
Balance
Minimum [Member]
Minimum [Member]
Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]
Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments
Bonds [Member]
Agency bonds [Member]
Revenues from related parties
Revenues
Revenues, Total
Significant Accounting Policies [Text Block]
Significant Accounting Policies
Operating Lease, Liability
Operating lease liability
Present value of lease liabilities
Operating Lease, Liability, Total
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
Expected volatility, minimum
Beijing Kangda Yongfu Pharmaceutical Co., LTD.
Beijing Kangda Yongfu Pharmaceutical Co L T D [Member]
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member]
Disaggregation of Revenue [Abstract]
Equity Component [Domain]
Equity Component
Employee stock options [Member]
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities:
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Less: Unamortized issuance costs
Less: Unamortized issuance costs
Measurement Frequency [Axis]
Measurement Frequency
Debt Disclosure [Abstract]
Entity Current Reporting Status
Entity Current Reporting Status
Common Stock, Shares Authorized
Common stock, shares authorized
Acquired in-process research and development expenses
Research and Development Expense
Research and development
Research and Development Expense, Total
Contract With Customer Liability [Table]
Contract With Customer Liability [Table]
Contract With Customer Liability [Table]
Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Finance lease right-of-use assets
Finance lease right-of-use assets, net
Finance lease right-of-use assets
United states and rest of world.
United States And Rest Of World [Member]
U.S./RoW [Member]
Loss on asset acquisition
Loss on asset acquisition
Assets [Abstract]
Assets
Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.
Proceeds From Upfront Non Contingent Non Refundable And Time Based Payments
Upfront, non-contingent, non-refundable and time-based payments
Proceeds from sale of common stock
Proceeds from issuance of common stock under employee stock plans
Proceeds from Issuance of Common Stock
Contract with customer liability net of balance presented against contract asset.
Contract with customer liability net of balance presented against contract asset
Balance Presented Net Against Contract Asset
Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]
Common stock, $0.01 par value; 225,000 shares authorized at September 30, 2023 and December 31, 2022; 98,339 and 94,166 shares issued and outstanding at September 30, 2023 and December 31, 2022
Common Stock, Value, Issued
Common Stock, Value, Issued, Total
Common Stock, Value, Issued, Beginning Balance
Common Stock, Value, Issued, Ending Balance
Net transfer price.
Net Transfer Price [Member]
Net Transfer Price [Member]
Discounts and rebates.
Discounts And Rebates [Member]
Discounts and Rebates [Member]
Proceeds from Sale of Property, Plant, and Equipment, Total
Proceeds from Sale of Property, Plant, and Equipment
Proceeds from sale of property and equipment
Increase Decrease In Deferred Revenue [Member]
Increase decrease in deferred revenue.
Decrease (Increase) in Deferred Revenue [Member]
Contract with Customer, Liability, Revenue Recognized
Recognized as Revenue
Royalty revenue recognized as drug product revenue
Accrued Liabilities, Current
Total accrued and other current liabilities
Percentage of revenue interest on global net sales
Percentage Of Revenue Interest On Global Net Sales
Percentage of revenue interest on global net sales.
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents
Cash and cash equivalents
Current Fiscal Year End Date
Current Fiscal Year End Date
Share-Based Payment Arrangement, Noncash Expense
Stock-based compensation
Share-based Payment Arrangement, Noncash Expense, Total
Loss from operations
Operating Income (Loss)
SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]
SEC Schedule, 12-09, Valuation Allowances and Reserves Type
Co development information sharing and committee services.
Co Development Information Sharing And Committee Services [Member]
Co-development, information sharing & committee services [Member]
Schedule of maturities of finance and operating leases liabilities.
Schedule Of Maturities Of Finance And Operating Leases Liabilities Table [Text Block]
Schedule of Maturities of Finance and Operating Leases Liabilities
Business Combination, Consideration Transferred, Total
Business Combination, Consideration Transferred
Purchase consideration
Commitments and contingencies.
Commitments And Contingencies [Line Items]
Commitments And Contingencies [Line Items]
Income Tax Expense (Benefit)
Provision for income taxes
Income Tax Expense (Benefit), Total
Provision for (benefit from) income taxes
Research and Development Expense [Member]
Research and development [Member]
Milestone payments [Member]
Milestone payments.
Stock Issued During Period, Shares, Acquisitions
Consolidation of Fortis (Note 3)
Cash
Cash
Cash, Beginning Balance
Cash, Ending Balance
Cash payments for restructuring
Payments for Restructuring
Royalty Revenue [Member]
Royalty [Member]
Share-Based Payment Arrangement, Expense
Total stock-based compensation expense
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Expected volatility, maximum
Payment, Tax Withholding, Share-Based Payment Arrangement
Cash paid for payroll taxes on restricted stock unit releases
Disaggregation of Revenue [Table]
Disaggregation Of Revenue [Table]
Measurement Input Type [Domain]
Lease obligations non-current.
Lease Obligations Non-Current
Long-term portion of lease obligations
Deferred Revenue, Total
Deferred Revenue
Deferred revenue
Valuation Approach and Technique [Domain]
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Other comprehensive income (loss):
License [Member]
License Revenue [Member]
License [Member]
NovaQuest Capital Management.
NovaQuest Capital Management [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Earnings Per Share, Policy [Policy Text Block]
Net Income (Loss) per Share
Net Loss per Share
Other Nonoperating Income (Expense), Total
Other Nonoperating Income (Expense)
Other
Due to related parties deferred revenue current.
Due To Related Parties Deferred Revenue Current
Deferred revenue current to related party
Drug product revenue from related party.
Drug Product Revenue From Related Party
Drug product revenue from a related party
Deferred approval milestone.
Deferred Approval Milestone [Member]
Deferred Approval Milestone [Member]
Long-Term Debt, Type [Domain]
AstraZeneca AB.
AstraZenecaAB [Member]
Astra Zeneca [Member]
Recently issued and adopted accounting guidance.
Recently Issued And Adopted Accounting Guidance Policy [Text Block]
Recently Issued and Adopted Accounting Guidance
Subsequent Events [Abstract]
Maximum payment cap amount
Maximum payment cap amount
Maximum payment cap amount.
U.S. government bonds
US Government Securities, at Carrying Value
Due to related parties, noncurrent
Other Liabilities Noncurrent Due to Related Parties
Other liabilities noncurrent due to related parties.
Commitments and Contingencies Disclosure [Abstract]
Other Assets, Noncurrent
Other assets
Other Assets, Noncurrent, Total
Other Accrued Liabilities, Current
Other
At-the-Market Program
Equity [Text Block]
Depreciation
Depreciation
Depreciation, Total
Fair Value Of US Treasury Notes And Bills Transfered From Level One To Level Two
Fair value of US treasury notes and bills transfered from level one to level two.
Fair value of U.S. treasury notes and bills transfered from level 1 to level 2
Astellas agreement.
Astellas Agreement [Member]
Astellas Agreement [Member]
Alternative Investment, Measurement Input
Discount rate applied
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]
Summary of Amounts Recognized as Revenue
Additional Paid in Capital
Additional paid-in capital
Additional Paid in Capital, Total
Additional Paid in Capital, Beginning Balance
Additional Paid in Capital, Ending Balance
Equity method investment increase (decrease) from currency translation.
Equity Method Investment Increase Decrease From Currency Translation
Currency Translation
Manufacture and supply of pamrevlumab.
Manufacture And Supply Of Pamrevlumab [Member]
Manufacture and Supply of Pamrevlumab [Member]
Commitments and contingencies.
Commitments And Contingencies [Table]
Commitments And Contingencies [Table]
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Gross Unrealized Holding Gains
Increase (decrease) in operating lease right-of-use assets.
Increase Decrease In Operating Lease Right Of Use Assets
Operating lease right-of-use assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Lease, Cost [Table Text Block]
Components of Lease Expense
Represents the amount of milestone payments related to commercial sales under the collaborative agreement.
Commercial Sales Milestone
Commercial sales milestone
Repayments of Debt and Lease Obligation
Repayments of lease obligations
Received from sale of revenue
Received From Sale of Revenue
Received from sale of revenue.
Less: Current portion classified to accrued and other current liabilities
Liability Related To Sale Of Revenue Current
Liability related to sale of revenue current.
Earnings Per Share [Abstract]
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Change in unrealized gain or loss on investments
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total
Investment, Name [Domain]
The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition.
Cash Consideration Received Under Collaboration Agreement
Total Consideration
Accounting Policies [Abstract]
Sales Returns and Allowances [Member]
Sales Returns [Member]
Deferred for future recognition.
Deferred For Future Recognition [Member]
Constrained for Future Recognition [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable
Accounts payable
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets
Prepaid expenses and other current assets
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
Net identifiable assets, liabilities and non-controlling interests
Payment to options exercised
Payment to Options Exercised
Payment to options exercised
Stockholders' deficit:
Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Earnings Per Share, Basic
Earnings Per Share, Basic, Total
Basic
Net loss per share - basic
Asset acquisition policy.
Asset Acquisition Policy [Policy Text Block]
Asset Acquisition
Commitments and Contingencies
Commitments and Contingencies (Note 12)
Regulatory milestone.
Regulatory Milestones [Member]
Regulatory Milestone [Member]
Business Combinations [Abstract]
Acquisition and variable interest entity abstract.
Acquisition And Variable Interest Entity [Abstract]
Income Statement [Abstract]
China performance obligation.
China Performance Obligation [Member]
China performance obligation [Member]
Related Party, Type [Axis]
Related Party
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
Roll-forward of Related Contract Liabilities
Measurement Input Type [Axis]
Statistical Measurement [Domain]
Statistical Measurement
Net Cash Provided by (Used in) Operating Activities
Net cash used in operating activities
Astellas Europe Agreement [Member]
Astellas Europe Agreement [Member]
Astellas Europe Agreement.
Accrued co-promotion expenses - current.
Accrued Co Promotion Expenses Current
Accrued co-promotion expenses - current
Interest expense recognized
Non-cash interest expense related to sale of future revenues
Non Cash Interest Expense Related To Sale Of Future Revenues
Non cash interest expense related to sale of future revenues.
Document Period End Date
Document Period End Date
Statistical Measurement [Axis]
Statistical Measurement
Accounts Receivable, Allowance for Credit Loss
Reductions to gross accounts receivable
Accounts Receivable, Allowance for Credit Loss, Beginning Balance
Accounts Receivable, Allowance for Credit Loss, Ending Balance
Commitments and Contingencies Disclosure [Text Block]
Commitments and Contingencies
Stockholders' Equity Note [Abstract]
Cornea products.
Cornea Products [Member]
Cornea Products [Member]
Dividend Received
Dividend Received
Dividend received
Investment Income, Dividend
Earnings Per Share, Diluted
Earnings Per Share, Diluted, Total
Diluted
Net loss per share - diluted
Product development obligations
Product Development Costs
Product Development Costs
Product and Service [Domain]
Product and Service
Mark Eisner [Member]
Mark Eisner.
Contract with customer liability increase decrease in revenue due to changes to estimated variable consideration
Contract With Customer Liability Increase Decrease In Revenue Due To Changes To Estimated Variable Consideration
Contract with customer liability increase decrease in revenue due to changes to estimated variable consideration.
SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]
SEC Schedule, 12-09, Valuation Allowances and Reserves
Revenue from Contract with Customer [Abstract]
Revenue:
Delayed Draw Term Loan [Member]
Delayed draw term loan.
Debt Instrument, Name [Domain]
Fair Value Hierarchy and NAV [Domain]
Fair Value Hierarchy and NAV
Product revenue policy.
Product Revenue Policy Policy [Text Block]
Product Revenue, Net
Loss before income taxes
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Loss before income taxes
Drug product revenue.
Drug Product Revenue Policy [Text Block]
Drug Product Revenue
Increase (Decrease) in Other Noncurrent Liabilities
Other long-term liabilities
CHINA
China [Member]
Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement.
Development And Regulatory Approval Milestones
Development and regulatory approval milestones
Fair Value, Recurring [Member]
Fair Value, Measurements, Recurring [Member]
Profit share.
Profit Share [Member]
Profit Share [Member]
Number of Reportable Segments
Number of reportable segment
Liability Related to Sale of Future Revenues
Liability Related To Sale of Future Revenue [Text Block]
Liability related to sale of future revenue.
Nonredeemable Preferred Stock [Member]
Nonredeemable [Member]
Other Revenue - Patent Transfer [Member]
Other Revenue Patent Transfer [Member]
Other revenue patent transfer .
Redeemable non-controlling interests.
Redeemable non-controlling interests
Finite-Lived Intangible Assets, Major Class Name [Domain]
Finite-Lived Intangible Assets, Major Class Name
Accrued restructuring charges
Accrued Restructuring Charges
Accrued restructuring charges.
Shares issued from stock plans net of payroll taxes paid shares.
Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares
Shares issued from stock plans, net of payroll taxes paid, Shares
Long term investment excluding equity method investments.
Long Term Investment Excluding Equity Method Investments
Long-term investments
Liabilities and Equity [Abstract]
Liabilities, redeemable non-controlling interests and deficit
Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.
Potential Milestones
Potential milestone payments
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Entity Interactive Data Current
Entity Interactive Data Current
Selling and Marketing Expense, Total
Selling and Marketing Expense
Sales and marketing
Measurement Input, Discount Rate [Member]
Measurement Input Discount Rate [Member]
Increase (Decrease) in Accounts Payable
Accounts payable
Increase (Decrease) in Accounts Payable, Total
Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]
Summary of Available for Sale Securities in Unrealized Loss Position, Fair Value and Gross Unrealized Loss By Length of Time Security in Continual Unrealized Loss Position
Business combination, recognized identifiable assets acquired and liabilities assumed business combination, accrued and other current liabilities
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Business Combination, Accrued and other current liabilities
Accrued and other current liabilities
Billed Contracts Receivable
Payments to Acquire in Process Research and Development
Payment made for acquired in-process research and development asset
Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration.
Proceeds From Upfront Non Contingent And Time Based Payments
Upfront, non-contingent and time-based payments received
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Fair value of the acquired in process research and development assets.
Fair value of the acquired in process research and development assets
Fair value of the acquired IPR&D assets
Drug product revenue, net.
Drug Product Revenue, Net [Member]
Equity Components [Axis]
Equity Components
Convertible promissory note [Member]
Convertible promissory note [Member]
Convertible promissory note.
Increase (Decrease) in Accounts Receivable
Accounts receivable, net
Investments, Debt and Equity Securities [Abstract]
Maximum future milestone payments.
Maximum Future Milestone Payments
Maximum future milestone payments
Future revenue granted
Future revenue granted
Future revenue granted.
Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue.
Collaboration Services And Other Revenue
Collaboration services and other revenue from a related party
Proceeds from Sale, Maturity and Collection of Investments
Proceeds from maturities of investments
Proceeds from Sale, Maturity and Collection of Investments, Total
Secured Long-Term Debt, Noncurrent
Senior secured term loan facilities, non-current
Local Phone Number
Local Phone Number
Payment Cap Date on or before December 31, 2028 [Member]
Payment cap date on or before December thirty one two thousand twenty eight [Member]
Payment cap date on or before December thirty one two thousand twenty eight.
Astra Zeneca agreements.
Astra Zeneca Agreements [Member]
AstraZeneca Agreements [Member]
Loss Contingency, New Claims Filed, Number
Putative securities class action complaints filed
Statement of Cash Flows [Abstract]
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax [Abstract]
Available-for-sale investments:
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Accrued restructuring charge
Accrued Restructuring Charge Current
Accrued restructuring charge current.
Milestone payments
Milestone Payments
Milestone payments.
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to pre-clinical and clinical trial activities, including those performed by third parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Accrued Preclinical And Clinical Trial Current
Preclinical and clinical trial accruals
Common Stock, Par or Stated Value Per Share
Common stock, par value
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Effect of exchange rate change on cash and cash equivalents
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
Interest Income (Expense), Nonoperating, Net
Total interest and other, net
Senior secured term loan facilities.
Senior Secured Term Loan Facilities [Member]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Effective annual interest rate related to sale of future revenues
Effective Annual Interest Rate Related To Sale Of Future Revenues
Effective Annual Interest Rate Related To Sale Of Future Revenues
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Assets
Maximum [Member]
Maximum [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]
Liabilities
Christine Chung [Member]
Christine Chung.
Collaborative arrangement aggregate consideration for milestone and upfront payments.
Collaborative Arrangement Aggregate Consideration For Milestone And Upfront Payments
Aggregate consideration received for milestone and upfront payments
Unbilled upfront payment
Contract with customer liability.
Contract With Customer Liability [Line Items]
Contract with Customer Liability [Line Items]
ATM Program [Member]
ATM Program.
Schedule of Investments [Abstract]
Fair Value, Inputs, Level 3 [Member]
Level 3 [Member]
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Stock-based compensation
APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total
Fair Value, Recurring and Nonrecurring [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Ownership [Domain]
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Net decrease in cash and cash equivalents
Payment Cap Date after January 1, 2030 [Member]
Payment cap date after January one two thousand thirty [Member]
Payment cap date after January one two thousand thirty.
Fortis Therapeutics.
Fortis Therapeutics [Member]
Fortis Therapeutics [Member]
Accrued Liabilities, Total
Accrued Liabilities
Accrued liabilities
Schedule of lease term and discount rate.
Schedule Of Lease Term And Discount Rate Table [Text Block]
Schedule of Lease Term and Discount Rate
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share
Schedule of Inventory, Current [Table Text Block]
Schedule of Inventory
Agency bonds.
Agency Bonds [Member]
Agency bonds [Member]
Increase (decrease) in operating lease liabilities, non-current.
Increase Decrease In Operating Lease Liabilities Non Current
Operating lease liabilities, non-current
City Area Code
City Area Code
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
Research and Development Arrangement, Contract to Perform for Others, Type
Inventory, Net
Inventories
Total inventories
Net Cash Provided by (Used in) Operating Activities [Abstract]
Operating activities
Accounting policy.
Accounting Policy [Line Items]
Accounting Policy [Line Items]
Interest Income, Other
Interest income
Payment Period One [Member]
Payment Period One [Member]
Restricted Cash and Cash Equivalents, Noncurrent
Restricted time deposits
Restricted Cash and Cash Equivalents, Noncurrent, Total
Business Acquisition [Line Items]
Acquisition and variable interest entity table.
Acquisition And Variable Interest Entity [Table]
Acquisition And Variable Interest Entity [Table]
Litigation settlement
Litigation Settlement Current
Litigation settlement current.
Gross accounts receivable.
Gross Accounts Receivable [Member]
Gross Accounts Receivable [Member]
General and Administrative Expense, Total
General and Administrative Expense
General and administrative
JAPAN
Japan [Member]
Selling, General and Administrative Expenses [Member]
Selling, general and administrative [Member]
Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment, Total
Debt Securities, Available-for-Sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment
Realized loss on sales of available-for-sale securities
Realized loss on sales of available-for-sale securities
Weighted Average Number of Shares Outstanding, Basic
Weighted Average Number of Shares Outstanding, Basic, Total
Basic
Basic
Falikang.
Falikang [Member]
Falikang [Member]
Research and Development Arrangement, Contract to Perform for Others, Type [Domain]
Research and Development Arrangement, Contract to Perform for Others, Type
Inventory, Work in Process, Gross
Work-in-progress
Employee Stock [Member]
ESPP [Member]
E U supply and Astellas agreement.
E U Supply And Astellas Agreement [Member]
Net Cash Provided by (Used in) Financing Activities [Abstract]
Financing activities
Rebates and discounts.
Rebates And Discounts [Member]
Rebates and Discounts [Member]
Statement [Table]
Statement [Table]
Schedule of Related Party Transactions, by Related Party [Table]
Schedule Of Related Party Transactions By Related Party [Table]
Increase (Decrease) in Contract with Customer, Liability
Deferred revenue
Development Revenue [Member]
Development revenue.
Document Fiscal Period Focus
Document Fiscal Period Focus
Other investors.
Other Investors [Member]
Investment income in unconsolidated variable interest entity
Income (Loss) from Equity Method Investments, Total
Share of Net Income
Investment income (loss)
Investment income (loss)
Related Party Transactions Disclosure [Text Block]
Related Party Transactions
Accrued Professional Fees, Current
Professional services
Statement [Line Items]
Statement [Line Items]
Schedule of Long-Term Debt Instruments [Table Text Block]
Summary of Senior Secured Term Loan Facilities
Contract with customer milestone method.
Contract With Customer Milestone Method Table [Text Block]
Summary of License Revenue and Development Revenue Recognized under Agreement
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Anti-dilutive shares outstanding
Anti-dilutive securities excluded from computation of net loss per share
Unamortized issuance costs and transaction costs.
Unamortized Issuance Costs and Transaction Costs
Less: Unamortized issuance costs and transaction costs
Less: Unamortized issuance costs and transaction costs
Subsequent Event [Line Items]
Adjustments to additional paid in capital shares issued from stock plans net of payroll taxes paid.
Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid
Shares issued from stock plans, net of payroll taxes paid
Future manufacturing clinical regulatory and commercial milestone payments.
Future Manufacturing Clinical Regulatory And Commercial Milestone Payments
Future manufacturing clinical regulatory and commercial milestone payments
Accounts receivable from related parties
Accounts receivable, net ($22,916 and $12,088 from related parties)
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts Receivable, after Allowance for Credit Loss, Current, Total
Common Stock [Member]
Common Stock [Member]
Debt Instrument [Line Items]
Direct sales.
Direct Sales [Member]
Direct Sales [Member]
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents
Total cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value, Beginning Balance
Cash and Cash Equivalents, at Carrying Value, Ending Balance
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Schedule of Recorded Stock-Based Compensation Expense
Corporate Bond Securities [Member]
Corporate bonds [Member]
Accretion (Amortization) of Discounts and Premiums, Investments
Net accretion of premium and discount on investments
Entity Common Stock, Shares Outstanding
Entity Common Stock Shares Outstanding
Accounts payable
Accounts Payable
Accounts Payable, Total
Litigation settlement amount
Loss Contingency Accrual
Loss Contingency Accrual, Ending Balance
Loss Contingency Accrual, Beginning Balance
Inventory, Finished Goods, Gross
Finished goods
Inventory, Finished Goods, Gross, Total
Antidilutive Securities, Name [Domain]
Revenue interest payment
Revenue interest payment
Revenue interest payment.
Collaborative arrangement additional upfront Amount.
Collaborative Arrangement Additional Upfront Amount
Additional upfront payments
Acquisition and variable interest entity line items.
Acquisition And Variable Interest Entity [Line Items]
Acquisition And Variable Interest Entity [Line Items]
Beijing Falikang Pharmaceutical Co. Ltd.
Beijing Falikang Pharmaceutical Co Ltd [Member]
Beijing Falikang Pharmaceutical Co Ltd
Beijing Falikang Pharmaceutical Co. Ltd [Member]
Cover [Abstract]
Dividend received from unconsolidated variable interest entity
Dividend Received from Unconsolidated Variable Interest Entity
Dividend received from unconsolidated variable interest entity.
Selling, General and Administrative Expense
Selling, general and administrative
Selling, General and Administrative Expense, Total
Long-Term Purchase Commitment, Category of Item Purchased [Domain]
Long-term Purchase Commitment, Category of Item Purchased
Document Fiscal Year Focus
Document Fiscal Year Focus
Liability related to sale of future revenues, non-current
Liability Related To Sale Of Future Revenues Non Current
Liability related to sale of future revenues non current.
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3
Transfers of assets out of level 3
Fair value of U.S. treasury notes and bills transfered from level 1 to level 2
Fair Value Of Us Treasury Notes And Bills Transfered From Level One To Level Two1
Fair value of US treasury notes and bills transfered from level one to level two.
Research and Preclinical Stage Development Programs [Member]
Research and pre-clinical stage development programs.
Research And Pre Clinical Stage Development Programs [Member]
Share-Based Payment Arrangement [Policy Text Block]
Stock-Based Compensation
Net unbilled milestone and co-development revenue
Supplies, net.
Supplies Net
Net unbilled co-development revenue
Net unbilled contract assets
Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue.
Collaborative Arrangement Aggregate Consideration Excluding Drug Product Revenue
Aggregate consideration received excluding drug product revenue
RSUs, PRSUs and TSR awards [Member]
RSUs, PRSUs and TSR Awards [Member]
RSUs, PRSUs and TSR Awards [Member]
Bond and mutual funds.
Bond And Mutual Funds [Member]
Bond and mutual funds [Member]
Security Exchange Name
Security Exchange Name
Schedule of Cash and Cash Equivalents [Table Text Block]
Schedule of Cash and Cash Equivalents
Preferred Stock, Shares Issued
Preferred stock, shares issued
Preferred Stock, Shares Issued, Total
Preferred Stock, Shares Authorized
Preferred stock, shares authorized
Third party shareholders.
Third Party Shareholders [Member]
Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.
Proceeds From Upfront Non Contingent And Non Refundable Payments
Proceeds from upfront, non-contingent and non-refundable payments
Business Acquisition, Acquiree [Domain]
Business Acquisition, Acquiree
Upfront payment.
Upfront Payment
Upfront payment
Financial Instrument [Axis]
Entity Emerging Growth Company
Entity Emerging Growth Company
Business Acquisition, Percentage of Voting Interests Acquired
Percentage of outstanding shares acquired
Amendment Flag
Amendment Flag
Transaction Type [Axis]
Transaction Type
Transaction price, variable consideration from estimated future co-development billing
Variable consideration payment received from estimated future co-development billing.
Variable Consideration Payment Received From Estimated Future Co Development Billing
Transaction price, variable consideration from estimated future co-development billing
Schedule of Accrued Liabilities [Table Text Block]
Schedule of Accrued and Other Current Liabilities
Revenue gross transfer price from contract with customer excluding assessed tax.
Revenue Gross Transfer Price From Contract With Customer Excluding Assessed Tax
Gross transfer price
Restructuring charge
Restructuring Charge [Policy Text Block]
Restructuring charge.
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Gross Unrealized Holding Losses
Gross Unrealized Holding Losses
Manufacturing related milestone payments
Manufacturing Related Milestone Payments
Manufacturing related milestone payment.
Accounting Standards Update [Domain]
Accounting Standards Update
Collaborative arrangements license agreement and revenues.
Collaborative Arrangements License Agreement And Revenues Disclosure [Text Block]
Collaboration Agreements, License Agreement and Revenues
Proceeds from Issuance of Secured Debt
Proceeds from senior secured term loan facilities, net of issuance costs
Equity Method Investment, Ownership Percentage
Ownership Percentage
Ownership percentage
Finance Lease, Right-of-Use Asset, Amortization
Amortization of finance lease right-of-use assets
Amortization of right-of-use assets
Category of Item Purchased [Axis]
Category of Item Purchased
Purchases of available-for-sale securities
Payments to Acquire Debt Securities, Available-for-Sale
Purchases of available-for-sale securities
Leases [Abstract]
Debt Securities, Available-for-Sale, Unrealized Loss Position
Available for sale securities in continual unrealized loss position, estimated fair value
Available for sale securities in continual unrealized loss position, estimated fair value
Securities Act File Number
Entity File Number
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Transaction price allocated to performance obligations.
Transaction Price Allocated To Performance Obligations
Transaction price and allocated to performance obligations
Liability related to sale of future revenues - ending balance
Liability related to sale of future revenues - beginning balance
Liability Related To Sale Of Future Revenues
Liability related to sale of future revenues.
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Due to related parties
Other Liabilities
Other Liabilities, Total
Long-term Debt, Excluding Current Maturities, Total
Long-Term Debt, Excluding Current Maturities
Long-term debt, less current portion
Senior secured term loan facilities, non-current
Unrealized gain (loss) on investments, net of tax effect
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
Increase in deferred revenue.
Increase In Deferred Revenue [Member]
Increase in Deferred Revenue [Member]
Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date.
Cumulative Revenue License And Development Revenue Recognized
Cumulative Revenue
Share-Based Payment Arrangement [Abstract]
Schedule of supplemental cash flow information related to leases.
Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]
Schedule of Supplemental Cash Flow Information Related to Leases
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities
Total liabilities
Juan Graham [Member]
Juan Graham.
Accounts payable
Accounts Payable, Current
Accounts Payable, Current, Total
Debt Instrument [Axis]
Costs and Expenses
Total operating costs and expenses
Accrued and other current liabilities ($29,157 and $63,886 to a related party)
Accrued Liabilities and Other Liabilities
Accrued Liabilities and Other Liabilities, Total
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Expected term (in years)
Collaborative Arrangement [Member]
Collaborative Arrangement [Member]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage
Percentage of outstanding shares owned
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at September 30, 2023 and December 31, 2022
Preferred Stock, Value, Issued
Preferred Stock, Value, Issued, Total
Preferred Stock, Value, Issued, Beginning Balance
Preferred Stock, Value, Issued, Ending Balance
Entity Small Business
Entity Small Business
Entity Shell Company
Entity Shell Company
Investment Type [Axis]
Investment Type
Payment for Contingent Consideration Liability, Investing Activities
Contingent payment associated with business acquisition
Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs.
Percentage Of Funding For Costs
Percentage of joint development costs committed to fund
Business combination, recognized identifiable assets acquired and liabilities assumed in-process research and development.
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed In-Process Research and Development
IPR&D assets
Contract with customer liability additions.
Contract With Customer Liability Additions
Additions
Commercial Paper [Member]
Commercial paper [Member]
Entity Address, Address Line One
Entity Address, Address Line One
Cash and Cash Equivalents, Fair Value Disclosure
Assets fair value disclosure
Contractual Obligation
Outstanding non-cancelable purchase obligations
Contractual Obligation, Total
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Burdened manufacturing costs
Manufacturing Costs
Antidilutive Securities [Axis]
Supplemental Balance Sheet Disclosures [Text Block]
Balance Sheet Components
Debt Instrument, Interest Rate During Period
Interest rate per annum
Subsequent Event Type [Domain]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Risk-free interest rate, minimum
Income Statement Location [Axis]
Income Statement Location
United States/Rest of World and China.
United States Rest Of World And China [Member]
U.S./RoW and China [Member]
License agreement with Eluminex.
License Agreement With Eluminex [Member]
Eluminex [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Risk-free interest rate, maximum
Fair value assets level1 to level2 transfer amount.
Fair Value Assets Level1 To Level2 Transfer Amount
Transfers of assets from level 1 to 2
Cost, Product and Service [Extensible Enumeration]
Cost, Product and Service [Extensible List]
Geographic Distribution [Domain]
Geographic Distribution
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Expected dividend yield
Contract with Customer, Liability [Abstract]
Long-Term Debt, Type [Axis]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Fair Value, Inputs, Level 2 [Member]
Level 2 [Member]
Product [Member]
Product Revenue, Net [Member]
Product [Member]
Equity Method Investments
Ending balance
Beginning balance
Equity method investment in unconsolidated variable interest entity
Equity method investments
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Liability Related to Sale of Future Royalties [Abstract]
Liability related to sale of future royalties.
Risks and uncertainties.
Risks And Uncertainties Policy [Text Block]
Risks and Uncertainties
Long-Term Debt, Gross
Amount received
Principal of senior secured term loan facilities
Product and Service [Axis]
Product and Service
Deferred revenue, net of current
Contract with Customer, Liability, Noncurrent
Astellas.
Astellas [Member]
Astellas [Member]
Title of 12(b) Security
Title of 12(b) Security
Foreign Government Debt [Member]
Foreign government bonds [Member]
Equity Securities [Member]
Equity investments [Member]
Money Market Funds, at Carrying Value
Money market funds
Payment Period Two [Member]
Payment period two.
Restructuring and Related Cost, Expected Number of Positions Eliminated
Restructuring plan, expected reduction to workforce
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
Fair Values of Financial Assets Measured on Recurring Basis
Investments [Domain]
Investments
Accounting Standards Update [Axis]
Accounting Standards Update
Schedule of Investments [Table]
Impairment loss on debt securities available for sale.
Impairment Loss On Debt Securities Available For Sale
Impairment loss
Net Cash Provided by (Used in) Investing Activities [Abstract]
Investing activities
U.S. government bonds.
U S Government Bonds [Member]
U.S. government bonds [Member]
Subsequent Event [Table]
Schedule of drug product revenue.
Schedule Of Drug Product Revenue Table [Text Block]
Schedule of Drug Product Revenue
Increase (Decrease) in Inventories
Inventories
Increase (Decrease) in Inventories, Total
Balance at December 31, 2022
Contract with Customer, Liability
Deferred Revenue
Deferred revenue
Deferred revenues from associated contracts
Contract with Customer, Liability, Total
Balance at June 30, 2023
Commercial Paper, at Carrying Value
Commercial paper
Percentage of revenue sold
Percentage of revenue sold
Percentage of revenue sold.
Jeffrey Henderson [Member]
Jeffrey Henderson.
Interest Expense, Debt, Total
Interest Expense, Debt
Interest expense
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
Available for sale securities in continual unrealized loss position, gross unrealized holding losses
Available for sale securities in continual unrealized loss position, gross unrealized holding losses
Available for sale securities in continual unrealized loss position, gross unrealized holding losses
Delayed Draw Term Loan 2
Delayed Draw Term Loan Two [Member]
Delayed draw term loan two.
Common Stock, Shares, Outstanding
Common stock, shares outstanding
Common Stock, Shares, Outstanding, Beginning Balance
Common Stock, Shares, Outstanding, Ending Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Risk-free interest rate
Share-Based Payment Arrangement [Text Block]
Stock-Based Compensation
Amortization of debt issuance costs and related transaction costs.
Amortization of Debt Issuance Costs and Related Transaction Costs
Issuance costs and related transaction costs, amortised
Revenue gross from contract with customer excluding assessed tax.
Revenue Gross From Contract With Customer Excluding Assessed Tax
Gross revenue
FibroGen Beijing.
Fibro Gen Beijing [Member]
FibroGen Beijing [Member]
Contract with customer, liability, increase (decrease) from current translation and other.
Contract With Customer Liability Increase Decrease From Current Translation And Other
Currency Translation and Other
Revenue payment cap amount
Revenue Payment Cap Amount
Revenue payment cap amount.
Income Statement Location [Domain]
Income Statement Location
Document Type
Document Type
Ownership [Axis]
Nonconsolidated Investees, Other [Member]
Nonredeemable NCI [Member]
Net cash provided by investing activities
Net Cash Provided by (Used in) Investing Activities
Document Quarterly Report
Document Quarterly Report
Share-Based Payment Arrangement [Member]
2014 Employee Share Purchase Plan [Member]
Counterparty Name [Domain]
Redeemable Preferred Stock [Member]
Redeemable [Member]
Product revenue from a related party.
Product Revenue
Product revenue from a related party
Net cash provided by (used in) financing activities
Net Cash Provided by (Used in) Financing Activities
Entity Filer Category
Entity Filer Category
Impairment of investment
Other than Temporary Impairment Losses, Investments
Balance Sheet Location [Domain]
Balance Sheet Location
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
Foreign currency translation adjustments
Foreign currency translation adjustments
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total
Accrued Liabilities, Current [Abstract]
Short-Term Investments
Short-term investments
Short-term Investments, Total
Schedule Of Activity Of Liability Related To Sale Of Future Revenues [Table Text Block]
Schedule of activity of liability related to sale of future revenues.
Schedule of Activities of Liability Related to Sale of Future Revenues
Revenue Recognition, Multiple-deliverable Arrangements [Table]
Revenue Recognition Multiple Deliverable Arrangements [Table]
Nonoperating Income (Expense)
Interest income and other income (expenses), net
Interest income and other income (expenses), net
Accrued profit share current.
Accrued Profit Share Current
Roxadustat profit share to AstraZeneca
Liabilities
Total liabilities
Current portion of lease financing obligations.
Current portion of lease financing obligations
Equity, Attributable to Parent
Stockholders' Equity Attributable to Parent, Beginning Balance
Stockholders' Equity Attributable to Parent, Ending Balance
Total stockholders' deficit attributable to FibroGen
Net loss
Net loss
Nonoperating Income (Expense) [Abstract]
Interest and other, net
Interest Expense
Interest expense
Interest Expense, Total
Proceeds from issuance of common stock under ATM Program, net of commissions
Proceeds from Issuance Initial Public Offering
Geographic Distribution [Axis]
Geographic Distribution
Contract asset
Contract with Customer, Asset, after Allowance for Credit Loss, Current
Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total
Bulk drug product.
Bulk Drug Product [Member]
Manufacture and Supply of Roxadustat.
Manufacture And Supply Of Roxadustat [Member]
Manufacture and Supply of Roxadustat [Member]
Award Date [Axis]
Statement of Financial Position [Abstract]
Weighted Average Number of Shares Outstanding, Diluted
Diluted
Diluted
Diluted
Acquired In-process Research and Development Expenses
Acquired in-process research and development expenses.
Weighted-average offering prices per share
Weighted-Average Offering Prices Per Share
Weighted-average offering prices per share
Investment income in unconsolidated variable interest entity
Investment (gain) loss in unconsolidated variable interest entity.
Investment Gain Loss In Unconsolidated Variable Interest Entity
Leases.
Leases
Accrued litigation settlement
Accrued Litigation Settlement
accrued litigation settlement.
Debt Securities, Available-for-Sale, Amortized Cost
Amortized Cost
Amortized Cost
Accrued restructuring charge
Restructuring Reserve, Current
Increase (decrease) in accrued interest for finance lease liabilities.
Increase Decrease In Accrued Interest For Finance Lease Liabilities
Accrued interest for finance lease liabilities
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
Income Tax Disclosure [Text Block]
Income Taxes
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets
Total assets
Accounting policy.
Accounting Policy [Table]
Accounting Policy [Table]
Other Purchases.
Other Purchases [Member]
Other Purchases [Member]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Summary of Reconciliation of Basic and Diluted Net Income (Loss) Per Share Calculation
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total
Other-than-temporary impairment loss
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
Current portion of liability related to sale of future revenues
Liability Related To Sale Of Future Revenues Current
Liability related to sale of future revenues current.
Valuation Approach and Technique [Axis]
Disaggregation of Revenue [Line Items]
Disaggregation Of Revenue [Line Items]
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
Available for sale securities in continual unrealized loss position, 12 months or more, gross unrealized holding losses
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Fair Value Disclosures [Abstract]
Fair Value Hierarchy and NAV [Axis]
Level 1 [Member]
Measurement Frequency [Domain]
Measurement Frequency
License and development.
License And Development [Member]
License and Development [Member]
Payments to Acquire Property, Plant, and Equipment
Purchases of property and equipment
Payments to Acquire Property, Plant, and Equipment, Total
Contract with customer liability reclassified to accrued liability.
Contract With Customer Liability Reclassified to Accrued Liability
Reclassified to Accrued Liability
Geographic Distribution, Foreign [Member]
Foreign subsidiaries [Member]
Sales to Falikang.
Sales To Falikang [Member]
Sales To Falikang [Member]
Issuance of common stock under ATM Program shares
Stock Issued During Period, Shares, New Issues
Employee-related Liabilities, Current
Payroll and related accruals
Employee-related Liabilities, Current, Total
Business Acquisition [Axis]
Business Acquisition
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Total cash and cash equivalents at end of period
Total cash and cash equivalents at beginning of period
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
Income Tax Disclosure [Abstract]
Finite-Lived Intangible Assets by Major Class [Axis]
Finite-Lived Intangible Assets by Major Class